CRIS - キュ―リス (Curis Inc.) キュ―リス

 CRISのチャート


 CRISの企業情報

symbol CRIS
会社名 Curis Inc (キュ―リス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 キュリス(Curis Inc.)は癌治療薬の開発、商業化を求めるバイオテクノロジー企業である。同社の薬品候補は経口可能なヒストン脱アセチル化酵素(HDAC)の小分子阻害剤CUDC-907、ホスファチジルイノシトール-3-キナーゼ(PI3K)酵素を含む。CUDC-907はクラスI、IIのHDAC、及びクラスIのPI3K酵素の経口二重阻害剤である。CA-170は免疫活性化の負の調節因子として独立して機能するプログラムされた死亡リガンド-1(PDL1)およびT細胞活性化のVドメインIgサプレッサー(VISTA)免疫チェックポイントタンパク質を選択的に標的化するために設計される経口小分子薬物候補である。CA-4948はトール様受容体またはある種のインターロイキン受容体シグナル伝達経路のトランスデューサであるインターロイキン-1受容体関連キナーゼ4(IRAK4)キナーゼを阻害するために設計される経口小分子薬物候補である。   キュ―リスは、癌治療の研究開発に従事する米国企業。社内および共同で研究開発プログラムを行っている。癌薬剤候補は、リンパ腫および多発性骨髄腫治療の「CUDC-907」、固形腫瘍およびリンパ腫治療の「CUDC-427」、高度な基底細胞癌の治療のために承認された薬「Erivedge」がある。   Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
本社所在地 4 Maguire Road Lexington MA 02421 USA
代表者氏名 James R. McNab ジェームズ・R・マクナブ
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-503-6500
設立年月日 36557
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 55人
url www.curis.com
nasdaq_url https://www.nasdaq.com/symbol/cris
adr_tso
EBITDA EBITDA(百万ドル) -39.14600
終値(lastsale) 1.92
時価総額(marketcap) 63707800.32
時価総額 時価総額(百万ドル) 65.03505
売上高 売上高(百万ドル) 10.53200
企業価値(EV) 企業価値(EV)(百万ドル) 63.11205
当期純利益 当期純利益(百万ドル) -42.89600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Curis Inc. revenues increased 15% to $4.8M. Net loss decreased 35% to $19.4M. Revenues reflect Royalties increase of 13% to $4.9M Research and development net increase of 58% to -$42K. Lower net loss reflects Research_development Expenses B/F decrease of 42% to $13.9M (expense) Stock-Based Compensation Expense in SGA decrease of 21% to $1.6M (expense).

 CRISのテクニカル分析


 CRISのニュース

   Soon, you can get your train tickets verified by examiner without any physical contact  2020/07/23 13:07:00 The New Indian Express
The Centre of Railway Information System (CRIS), an IT arm of IRCTC, has rolled out the application, which was developed by the Prayagraj division of the North Central Railway, across the country
   Curis Announces $17.5 Million Registered Direct Offering  2020/06/11 13:25:00 PR Newswire
LEXINGTON, Mass., June 11, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into definitive agreements with fundamental healthcare investors for…
   The 'Important Step' For Nano-Cap Biopharma Curis That's Sending Shares Higher  2020/06/10 14:40:14 Benzinga
Shares of nano-cap biopharma Curis, Inc. (NASDAQ: CRIS ) are on a strong two-day run that has lifted the equity from penny stock territory. What Happened: The Lexington, Massachusetts-based company, which focuses on developing innovative therapies for treating cancer, said the FDA has cleared its investigational new drug application for its CI-8993 asset. CI-8993 is a monoclonal anti-VISTA antibody. It acts by blocking VISTA, which plays a key role in suppressing T-cell activity when activated. Blocking VISTA reduces the suppression of T-cells and anti-tumor … Full story available on Benzinga.com
   Why the FDA Is Pushing Curis Stock So Much Higher  2020/06/10 14:10:23 24/7 Wall street
   Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody  2020/06/10 12:00:00 PR Newswire
LEXINGTON, Mass., June 10, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug…
   Curis Reports First Quarter 2020 Financial Results  2020/05/12 20:01:00 Benzinga Feeds
LEXINGTON, Mass. , May 12, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS ), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2020 . "The first quarter of 2020 was productive for Curis, as we advanced our ongoing study for CA-4948 and accomplished several key licensing and financial objectives to support future progress across our pipeline and business," said James Dentzer , President and Chief Executive Officer of Curis. "In response to the COVID-19 pandemic, we have implemented both clinical and operational measures to help protect patients, staff, study investigators and our community, and I am incredibly proud of the resiliency and dedication our team continues to demonstrate during this difficult period. We look forward to updating efficacy data from our CA-4948 study in patients with non-Hodgkin's lymphoma (NHL) and remain on track to pursue clinical testing of CA-4948 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), two areas of critical unmet need." First Quarter 2020 and Recent Operational Highlights Precision oncology, CA-4948 (IRAK4 Inhibitor; Aurigene collaboration): Curis is evaluating its IRAK4 inhibitor, CA-4948 in an ongoing Phase 1 dose escalation study for the treatment of patients with relapsed or refractory (R/R) NHL, including patients with diffuse large B-cell lymphoma (DLBCL), Waldenström's macroglobulinemia (WM) and oncogenic MYD88 mutations.
   Curis to Release First Quarter 2020 Financial Results and Hold Conference Call on May 12, 2020  2020/05/05 12:00:00 PR Newswire
LEXINGTON, Mass., May 5, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2020 financial results on Tuesday, May 12,…
   Curis Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update  2020/03/19 20:01:00 PR Newswire
LEXINGTON, Mass., March 19, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2019. "Our…
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
   Curis Announces $30 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC  2020/02/27 13:00:00 PR Newswire
LEXINGTON, Mass., Feb. 27, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into a common stock purchase agreement (the "Agreement") of up to $30…
   Curis Reports First Quarter 2020 Financial Results  2020/05/12 20:01:00 Benzinga Feeds
LEXINGTON, Mass. , May 12, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS ), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2020 . "The first quarter of 2020 was productive for Curis, as we advanced our ongoing study for CA-4948 and accomplished several key licensing and financial objectives to support future progress across our pipeline and business," said James Dentzer , President and Chief Executive Officer of Curis. "In response to the COVID-19 pandemic, we have implemented both clinical and operational measures to help protect patients, staff, study investigators and our community, and I am incredibly proud of the resiliency and dedication our team continues to demonstrate during this difficult period. We look forward to updating efficacy data from our CA-4948 study in patients with non-Hodgkin's lymphoma (NHL) and remain on track to pursue clinical testing of CA-4948 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), two areas of critical unmet need." First Quarter 2020 and Recent Operational Highlights Precision oncology, CA-4948 (IRAK4 Inhibitor; Aurigene collaboration): Curis is evaluating its IRAK4 inhibitor, CA-4948 in an ongoing Phase 1 dose escalation study for the treatment of patients with relapsed or refractory (R/R) NHL, including patients with diffuse large B-cell lymphoma (DLBCL), Waldenström's macroglobulinemia (WM) and oncogenic MYD88 mutations.
   Curis to Release First Quarter 2020 Financial Results and Hold Conference Call on May 12, 2020  2020/05/05 12:00:00 PR Newswire
LEXINGTON, Mass., May 5, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2020 financial results on Tuesday, May 12,…
   Curis Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update  2020/03/19 20:01:00 PR Newswire
LEXINGTON, Mass., March 19, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2019. "Our…
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
   Curis Announces $30 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC  2020/02/27 13:00:00 PR Newswire
LEXINGTON, Mass., Feb. 27, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into a common stock purchase agreement (the "Agreement") of up to $30…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 キュ―リス CRIS Curis Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)